Prelude Capital Management’s Acumen Pharmaceuticals ABOS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-48,414
| Closed | -$83.3K | – | 1055 |
|
|
2024
Q4 | $83.3K | Sell |
48,414
-4,003
| -8% | -$6.89K | 0.01% | 981 |
|
|
2024
Q3 | $130K | Buy |
52,417
+6,007
| +13% | +$14.9K | 0.01% | 1025 |
|
|
2024
Q2 | $112K | Buy |
46,410
+9,410
| +25% | +$22.8K | 0.01% | 993 |
|
|
2024
Q1 | $150K | Buy |
37,000
+7,900
| +27% | +$32K | 0.01% | 1051 |
|
|
2023
Q4 | $112K | Buy |
+29,100
| New | +$112K | 0.01% | 888 |
|
|
2023
Q3 | – | Sell |
-31,100
| Closed | -$150K | – | 965 |
|
|
2023
Q2 | $150K | Buy |
+31,100
| New | +$150K | 0.01% | 766 |
|
|
2022
Q3 | – | Sell |
-18,500
| Closed | -$87K | – | 1454 |
|
|
2022
Q2 | $87K | Buy |
18,500
+2,900
| +19% | +$13.6K | ﹤0.01% | 1220 |
|
|
2022
Q1 | $61K | Buy |
+15,600
| New | +$61K | ﹤0.01% | 1181 |
|